HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
AssigneeHoffmann-La Roche Inc.
InventorsFiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
Life of this patent
Estimating the term…
Abstract
The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
Claims37
1-20. (canceled)
A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody
- i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO:
- 03, and/or
- ii) does not bind to full length human Tau (SEQ ID NO:
- 01) at 1 μg/mL, and/or
- iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO:
- 02), and/or
- iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO:
- 02), and/or
- v) specifically binds to human Tau that has the amino acid sequence of SEQ ID NO:
- 01 and that has the amino acid mutation S422A.
A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody comprises
- a) in the heavy chain variable domain the HVRs of SEQ ID NO:
- 08, 18 and 10, or
- b) in the heavy chain variable domain the HVRs of SEQ ID NO:
- 08, 09 and 10.
The pharmaceutical formulation according to claim 48, further comprising an anti-human alpha-synuclein antibody or an anti-Abeta antibody.
A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody
- i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO:
- 03, and
- ii) does not bind to full length human Tau (SEQ ID NO:
- 01) at 1 μg/mL, and
- iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO:
- 02), and
- iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO:
- 02), and
- v) specifically binds to human Tau that has the amino acid sequence of SEQ ID NO:
- 01 and that has the amino acid mutation S422A.
A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody
- i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO:
- 03, or
- ii) does not bind to full length human Tau (SEQ ID NO:
- 01) at 1 μg/mL, or
- iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO:
- 02), or
- iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO:
- 02), or
- v) specifically binds to human Tau that has the amino acid sequence of SEQ ID NO:
- 01 and that has the amino acid mutation S422A.
Dependencies are inferred from the claim text.